Screener
Amneal Pharmaceuticals, Inc. AMRX Long-Term Debt
Long-Term Debt at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtNoncurrent.
The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001723128-26-000031
FAQ
- What is Amneal Pharmaceuticals, Inc.'s long-term debt?
- Amneal Pharmaceuticals, Inc. (AMRX) reported long-term debt of $2.56B in Q2 2026.
- How has Amneal Pharmaceuticals, Inc.'s long-term debt changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s long-term debt increased by 19.5% year-over-year, from $2.15B to $2.56B.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s long-term debt?
- Over 5 years (2020 to 2025), Amneal Pharmaceuticals, Inc.'s long-term debt has grown at a -1.3% compound annual growth rate (CAGR), from $2.74B to $2.57B.
- What does long-term debt mean?
- Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.
Ask your AI about Amneal Pharmaceuticals, Inc.'s long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude